A liquid therapy placed underneath the tongues of people with peanut allergy can reduce their sensitivity to peanuts, a new study found. With further development, the experimental technique could make life easier for people whose only current option is to avoid everything that contains peanuts.
Food allergy comes about when the immune system responds to a harmless food as if it were a threat. Symptoms can range from hives and itching to a life-threatening condition called anaphylaxis, which can involve throat swelling, a sudden drop in blood pressure, trouble breathing, fainting and dizziness.
In both children and adults, peanuts are one of the most common foods to cause allergic reactions. About 3 out of every 500 people in the United States are allergic to peanuts. The only way to prevent the symptoms of food allergy is to avoid the food altogether. But it’s difficult to completely avoid exposure to peanuts and all the products made with them.
Recent studies have found that oral immunotherapy may hold promise for treating food allergy. A research team led by Dr. David M. Fleischer of National Jewish Health in Denver and Dr. A. Wesley Burks at the University of North Carolina set out to test whether an approach called sublingual immunotherapy could be used to treat peanut allergy. The medically supervised therapy involves placing a small amount of the allergy-causing substance (allergen) under the tongue to decrease the body’s sensitivity to the allergen.
The scientists enrolled 40 people, ages 12 to 37 years, with peanut allergy. All were on a peanut-free diet. After an initial food challenge to measure how much peanut powder they could eat without having an allergic reaction, participants were randomly assigned to receive sublingual immunotherapy or placebo. The therapy group received escalating doses of peanut powder every 2 weeks until a maintenance dose was reached. The trial was funded by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) and National Center for Advancing Translational Sciences (NCATS). Results appeared in the January 2013 issue of the Journal of Allergy and Clinical Immunology.
The researchers found that 14 of the 20 participants (70%) given peanut immunotherapy were able to consume at least 10 times more peanut powder after 44 weeks of daily therapy than they could at the beginning of the study. In contrast, only 3 of the 20 participants (15%) given placebo could safely consume such an increase. After 68 weeks, those on immunotherapy could consume significantly more peanut powder without having an allergic reaction than those given placebo. The therapy caused only minor side effects, such as itching in the mouth.
With more work, the scientists hope that sublingual immunotherapy could protect people from unintentional exposure to peanuts. “These results are encouraging,” Burks says. “The immune response was stronger than we thought it might be, and the side effects of this treatment were relatively small. However, the magnitude of the therapeutic effect was somewhat less than we had anticipated. That’s an issue we plan to address in future studies.”
This is one of several federally funded trials currently testing immune-based approaches to food allergy. The researchers caution that people should not try any of these techniques on their own because they carry a significant risk for allergic reactions. These therapies should be administered only under the guidance of trained clinicians.
Learn more: Therapy Shows Promise for Peanut Allergy
The Latest on: Peanut immunotherapy
via Google News
The Latest on: Peanut immunotherapy
- Peanut treatment lowers risk of severe allergic reactions in preschoolers, study findson December 4, 2020 at 8:32 am
A new study demonstrates that exposing children to a small, regular dose of an allergen (in this case, peanuts) in a real-world setting (outside of a clinical trial) is effective in reducing the risk ...
- Peanut treatment lowers risk of severe allergic reactionson December 3, 2020 at 10:14 pm
A new study by researchers at the University of British Columbia and BC Children Hospital gives hope to parents and kids who face real danger from exposure to ...
- Study offers hope to parents and kids who face real danger from peanut exposureon December 3, 2020 at 6:17 pm
It's a peanut-filled world--or at least it can feel that way for kids with peanut allergies. But a new study by researchers at the University of British Columbia and BC Children's Hospital gives hope ...
- Peanut treatment lowers risk of severe allergic reactions in preschoolerson December 3, 2020 at 1:15 pm
It's a peanut-filled world—or at least it can feel that way for kids with peanut allergies. But a new study by researchers at the University of British Columbia and BC Children's Hospital gives hope ...
- Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]on November 24, 2020 at 9:57 am
suggested remit : To appraise the clinical and cost effectiveness of Epicutaneous immunotherapy skin patch within its marketing authorisation for treating Allergy (peanut, children) ...
- DBV Technologies Announces Leadership Changeson November 24, 2020 at 12:52 am
Tax Planning Personal Finance Save for College Save for Retirement Invest in Retirement Research Mutual Funds Stocks ETFs Bonds Best Investments ...
- DBV Technologies Announces Leadership Changeson November 23, 2020 at 11:28 pm
including statements regarding the potential benefits of Viaskin Peanut, the Company's continued development of epicutaneous immunotherapy, and the Company's transition plans. These forward ...
- DBV Technologies Announces Leadership Changeson November 23, 2020 at 11:08 pm
This press release may contain forward-looking statements and estimates, including statements regarding the potential benefits of Viaskin Peanut, the Company’s continued development of ...
- Allergy Immunotherapy Market Size, Share 2020, Demand Overview, Technology Development, SWOT analysis, Applications, Key Companies Forecast to 2023on November 22, 2020 at 7:59 pm
The allergy type-based segments of the allergy immunotherapy market are allergic asthma, allergic rhinitis, cat allergy, and peanut allergy among others. The increase in pet adoption that is ...
via Bing News